{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028003","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.905277+00:00","generated_at":"2026-06-24T03:57:42.702878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Schrödinger Q2 revenue up 29% YoY to $38.5M; net loss widens to $47.7M, maintains 2022 outlook","bullets":["Software revenue $30.0M (+25% YoY); drug discovery revenue $8.5M (+48% YoY).","Net loss of $47.7M vs. $35.0M in Q2 2021; gross profit $17.1M (+43%).","Cash, equivalents, and marketable securities ~$513M, down from $529M at March 31, 2022.","IND for MALT1 inhibitor SGR-1505 cleared; Phase 1 trial in B-cell lymphoma expected Q4 2022.","Maintains full-year 2022 guidance: total revenue $161M–$181M, software revenue $126M–$136M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028003","json":"https://secwatch.observer/filing/0001564590-22-028003.json","markdown":"https://secwatch.observer/filing/0001564590-22-028003.md","text":"https://secwatch.observer/filing/0001564590-22-028003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000156459022028003/0001564590-22-028003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000156459022028003/sdgr-8k_20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:57:42.702878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}